Simcere’s ENZESHU® and ENDOSTAR® Included in China’s National Reimbursement Drug List
I'm PortAI, I can summarize articles.
Simcere Pharmaceutical Group Limited announced that its drugs ENZESHU® and ENDOSTAR® have been included in China's National Reimbursement Drug List. ENZESHU® is approved for certain cancers, while ENDOSTAR® treats advanced non-small cell lung cancer. This inclusion is expected to improve market positioning and patient access. The latest analyst rating for Simcere's stock (HK:2096) is a Buy with a HK$16.30 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments